Exxel Pharma (“Exxel” or “The Company”) is a development stage company that combines world-class leadership, expert technological know-how and experience from the pharmaceutical industry to develop medicines for significant unmet medical needs.
The Company is focused on development of small-molecule therapeutics for safe, non-addictive treatment of a pain, PTSD and substance (e.g. opioid) use disorders. Exxel is specifically targeting disease areas with significant unmet medical needs and aims to become the leader in therapeutics that enhance endocannabinoid signaling by FAAH inhibition.
Exxel Pharma’s pipeline counts two functionally distinct FAAH inhibitors, URB597 and URB937. URB597 is globally active, whereas URB937 is peripherally restricted (i.e., it does not enter the brain and spinal cord). These were developed at the University of California, Irvine by our Chief Scientific Officer, Professor Daniele Piomelli, and are protected by multiple issued and pending patents. URB597 is being developed for treatment of PTSD and substance use disorders (e.g. Opioid and Cannabis Addiction). URB937 is positioned as a safe, non-addictive alternative to opiate and non-steroidal anti-inflammatory pain management drugs, and the lead indication is acute, post-operative pain.